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Abstract
Background: Spinal muscular atrophy (SMA) is an inherited neuromuscular dis-
order and a leading genetic cause of infant death worldwide. However, there is no
routine screening program for SMA in the UK. Lack of treatments and the inabil-
ity of screening tests to accurately predict disease severity are among the key rea-
sons implementation of screening has faltered in the UK. With the recent release
of the first therapy for SMA (Nusinersen), calls are being made for a reconsidera-
tion of this stance; however, very little is known about the views of the general
public.
Methods: An online survey was administered to 232 individuals with no prior
relationship with SMA to assess their attitudes toward a newborn screening pro-
gram for it. Results are compared with previously gathered data on the views of
SMA-affected families toward screening.
Results: Eighty-four percent of participants were in favor of newborn screening.
Key reasons for support were a belief that it would lead to better healthcare and
life expectancy for affected infants and facilitate informed decision-making for
future pregnancies. Key reasons for nonsupport were a belief in the potential for
significant negative impact on the family unit in terms of bonding and stress.
Conclusions: Public acceptability is a key component in the evaluation of any
potential screening program in the UK. This study demonstrates that newborn
screening for SMA is viewed largely positively by people unfamiliar with the
condition. The importance of early identification overrode all other social and eth-
ical concerns about screening for the majority of participants.
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1 | INTRODUCTION
With the development of technologies such as whole gen-
ome sequencing, population screening for increasing num-
bers of genetic disorders is now more feasible than ever
before. While many of the genetic disorders for which
screening could be introduced are considered rare, most
have limited treatment options, a substantial impact on
quality of life and unpredictable/variable trajectories (Rose,
2015). Genetic screening for such conditions, it has been
argued, would allow carrier parents the option of avoiding
the birth of an affected child (when carried out
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preconceptually or prenatally), or the timely introduction of
therapies or clinical trial enrollment (when carried out on
newborns). As well as earlier identification, newborn
genetic screening is also associated with what has been ter-
med ‘reproductive benefit’ (Bombard et al., 2009). That is,
through their identification as carriers, parents (as well as
their wider family) will be able to make informed decisions
in relation to any subsequent pregnancies (Botkin & Roth-
well, 2016). Moreover, some newborn genetic screening
programs, for example, that for cystic fibrosis in the UK,
are capable of not only identifying infants who have (or
will develop) cystic fibrosis, but also those infants who are
genetic carriers. Thus, the “reproductive benefit” of new-
born screening may potentially also be conferred on the
screened child.
Despite these possibilities for enhanced reproductive
options and/or treatments, however, the introduction of
newborn genetic screening for rare disorders is still some-
what controversial. This is particularly so when undertaken
through whole genome sequencing techniques which have
the capacity to generate large (and potentially unwieldy)
volumes of data and within which the boundaries between
pathogenic and nonpathogenic findings are not clear (Fried-
man, Goldenberg, Lister, Senecal, & Vears, 2017). The
presymptomatic genetic testing of children for incurable
and/or late-onset disorders, furthermore, has long been con-
sidered ethically problematic, primarily because the direct
benefits to the child are limited (Schmidt et al., 2012), and
indeed, there can be associated harms. These harms include
the possibility of false positive/negative results, the impact
of the results on the relationship between parent and child,
the loss of disease-free time and anxiety about the future
(Tluczek, Orland, & Cavanagh, 2011). Indeed, asymp-
tomatic children who are diagnosed with a late-onset condi-
tion shortly after birth have been described by
Timmermans & Buchbinder (2010) and Grob (2008) as
existing in “liminal” state: neither fully ill nor fully well,
with varying implications for roles, identities, and (familial)
relationships.
Aside from the implications for the child, ethical con-
cerns have also been raised around the possible limits on
informed consent for expanded newborn genetic screening
programs (Bailey, Skinner, Davis, Whitmarsh, & Powell,
2008; Taylor-Phillips et al., 2014). Members of the general
population approach genetic screening with little/no back-
ground knowledge of the condition for which they, or their
child will be screened, and research has demonstrated that
they are often entirely unprepared for a positive result
(Dankert-Roelse & Meerman, 1995; McClaren, Delatycki,
Collins, Metcalfe, & Aitken, 2008). Indeed, it has been
argued that in an age of expansive genomic screening, that
notions of informed consent may have to be adapted
(Himes et al., 2016; O’Neill, 2001; Rose, 2015).
With these benefits and concerns in mind, this paper
considers the attitudes of members of the general public
toward a potential newborn screening program for spinal
muscular atrophy (SMA), a condition for which newborn
screening is currently being considered, both in the UK
and in the USA. While our previous study outlined the
views of families living with SMA toward newborn screen-
ing (Boardman, Young, & Griffiths, 2017a,b,c), this pre-
sent study contrasts these findings with the views of
members of the general population who have no prior rela-
tionship with the condition. The analysis explores how far
newborn genetic screening is accepted among its intended
recipients, highlighting the degree to which prior knowl-
edge of the condition being screened for is a significant
factor in attitudes.
1.1 | Spinal muscular atrophy and newborn
genetic screening
Spinal muscular atrophy is a neurodegenerative disorder
primarily resulting from the degradation of the alpha motor
neurons which connect the spinal cord, resulting in pro-
gressive proximal muscle weakness (Munsat & Davies,
1992, 1996). Spinal muscular atrophy can be characterized
into different types (I–IV) based on time of onset and
achievement of motor milestones: Type I (severe, onset:
<1 year); Type II (intermediate, onset: 7–18 months); Type
III (mild, onset >2 years); and Type IV (mild, adult onset)
(Lunn & Wang, 2008; Wang & Lunn, 2008).
There are currently numerous tests that can be used to
diagnose SMA, including restriction fragment length poly-
morphism, multiplex ligation-dependent probe amplifica-
tion, and quantitative PCR (Ar Rochmah et al., 2017; Kato
et al., 2015; Kesari, Mukherjee, & Mittal, 2003; Ogino,
Leonard, Rennert, & Wilson, 2002; Ogino & Wilson,
2002; Xu, Ogino, Lip, Fang, & Wu, 2003). In addition,
there is now a noninvasive prenatal diagnostic analysis that
can diagnose SMA using blood from expecting mothers,
although due to the nature of the analysis, this test can only
be offered to mothers who already have a child diagnosed
with SMA, making it an unsuitable screening tool (Parks
et al., 2017).
As all forms of SMA are caused by mutations in the
telomeric survival motor neuron (SMN1) gene (Lefebvre,
Burglen, Frezal, Munnich, & Melki, 1998; Lefebvre et al.,
1995, 1997), the second copy of SMN (centomeric SMN;
SMN2) is an important disease-modifying gene (Lefebvre
et al., 1995). Indeed, SMN2 copy number has been
described by some researchers as being linked to disease
severity in the majority of cases (with higher numbers of
SMN2 copies being associated with milder pathology),
although this approach has been somewhat controversial,
and criticized for being overly simplistic without
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consideration of potential gene modifiers (Oprea et al.,
2008). In practice, therefore geno- and phenotype data are
taken into consideration when a symptomatic child is diag-
nosed with SMA (Gavrilov, Shi, Das, Gilliam, & Wang,
1998; Wadman et al., 2017; Wirth et al., 2006).
When SMA is diagnosed through a screening program,
however, there are unique challenges. The combined lack
of family history, together with a (potentially) asymp-
tomatic infant may make an accurate prognosis for the
child difficult (Prior et al., 2010). Indeed, a newborn
screening program would lead to the identification of not
only severely affected infants (those with type I SMA who
are unlikely to live past 18 months), but also those who
will go on to develop milder forms of the condition later in
life (Prior et al., 2010: p;. 1613). Given the vast spectrum
of presentations associated with SMA, a clear idea of the
likely course of the disease—and critically, whether the
child is expected to survive infancy—is of paramount
importance to new parents. Inability to provide accurate
information about type was indeed one of the key reasons
that SMA screening was not introduced in the UK after the
last public consultation (Cartwright, 2012).
Spinal muscular atrophy screening is currently in place
in several countries internationally, with Qatar implement-
ing compulsory premarital carrier screening, and countries,
such as Australia and Israel, offering screening as part of
state-subsidized healthcare programs (Boardman et al.,
2017b,c). Newborn screening for SMA has long been
called for within the US; however, efforts to introduce it
have been consistently thwarted by the absence of an effec-
tive therapy, a prerequisite for all new newborn screening
programs (Swoboda, 2010). The licensing of Nusinersen
(Spinraza) at the end of 2016, however, following promis-
ing results of phase I clinical trials (Chiriboga et al., 2017),
dramatically shifted the landscape of SMA newborn screen-
ing. Nusinersen therapy (administered via repeated intrathe-
cal injections) was demonstrated to have a significant
impact on the motor function and survival of type I
affected infants. As it has been demonstrated that Nusin-
ersen therapy is most effective when administered in
presymptomatic children (Bertini, Hwu, Reyna, Farwell, &
De, 2017), the case for the introduction of state-wide new-
born screening to identify infants before they become
symptomatic has been considerably strengthened in recent
months. Indeed, newborn screening for SMA is currently
under review for inclusion on the Federal Newborn Recom-
mended Uniform Screening Panel and in July 2017, Mis-
souri became the first state to mandate SMA newborn
screening. Within the UK, newborn screening for SMA is
considered periodically.
As well as the development of therapies, a small num-
ber of pilot studies have also been undertaken to demon-
strate both the feasibility of a newborn screening program
for SMA (Prior, 2010a,b,c; Prior et al., 2010), and limited
number of studies have also explored attitudes toward such
screening among parents (Rothwell, Anderson, Swoboda,
Stark, & Botkin, 2013), the general public (Lin et al.,
2016), and also families who live with SMA (Boardman
et al., 2017b; Wood et al., 2014). This paper contributes to
this increasingly important body of literature by exploring
attitudes toward newborn screening for SMA among a
large sample of people (n = 232) from the UK general
population, and offers a comparison with our previous
work with affected families.
2 | METHODS AND MATERIALS
2.1 | SMA screening survey and SMA
newborn screening survey (UK)
The SMA Screening Survey (UK) was developed from
qualitative interview data from interviews with people liv-
ing with SMA or their families, as described elsewhere
(Boardman et al., 2017a,b,c). For this study, questions
regarding newborn screening were selected and reproduced
in a shorter survey (UK NewGenPop Survey). Questions
used to assess the demographics of respondents were either
modified versions of, or directly taken from, questions used
in the 2011 UK Census survey. As participants had no pre-
vious experience with SMA, key information about the
condition, its inheritance and presentation was provided at
the start of the survey. Ethical approval of the survey was
awarded in July 2014 by the Biomedical and Scientific
Research Ethics Committee.
2.2 | Survey distribution
Quantitative data collection was carried out from January
to May 2017. The UK newborn survey was only available
online through the survey platform Qualtrics. Participants
were invited to complete the survey if they were over the
age of 18 and had no relationship with SMA. The survey
was distributed through social networking pages (Face-
book). All participants remained anonymous by distributing
the survey link generated by the Qualtrics platform: (http://
warwick.co1.qualtrics.com/jfe/form/SV_d1jLEuyn0o2 ha17).
The link was reusable and was unable to track identifying
information of respondents.
2.3 | Statistical analysis
Basic descriptive analysis was performed to show the per-
centage of respondents associated with each demographic
characteristic. Responses were stratified as follows: gender
(male 1 vs. other 0); age (18–25 years 1 vs. ≥26 years 0);
qualifications (degree 1 vs. other 0); religion (yes 1 vs.
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other 0). For responses to each question regarding newborn
screening, data were stratified as either strongly agree/agree
(1) or other (0). This allowed all positive views to be
assessed in comparison to those with negative or uncertain
views.
Percentages of respondents that answered either agree
(1) or other (0) to questions regarding newborn screening
were calculated and compared to the responses of people
with SMA and their families using a chi-square test.
Univariate binary logistic regression was performed to
find associations between those that had ‘agree’ responses
to each question regarding newborn screening and those
who stated they would support a newborn genetic screen-
ing program for SMA. This allowed for the effect of each
independent variable to be assessed. For those that had a
significant association, multivariate binary logistic regres-
sion was performed to find questions independently associ-
ated with the test variable. Last, in order to assess bias
among the demographics, forward multivariate binary
logistic regression using the identified main drivers, age,
gender, qualification, and religion as the independent vari-
ables was performed. During the course of the statistical
analysis, any probability value (p value) of <.05 was con-
sidered significant. All statistical analysis was performed
using IBM SPSS Statistics 24 software.
3 | RESULTS
3.1 | Comparative cohort descriptive
characteristics
The total number of respondents to the survey was 232. Of
the 232 participants, the majority were female (69%), aged
between 18 and 25 years of age (40%), educated to degree
level (49%), and had no religious faith (63%). There was
an almost even split of participants that had children and
those that did not (48% and 51.5%, respectively). Only 3%
of respondents were either pregnant or trying to get preg-
nant. All participants had no relationship with SMA
(Table 1).
3.2 | Newborn Genetic Screening
Of the 232 people surveyed, 84% of participants were in
favor of a newborn genetic screening program for SMA
(Table 2). This is significantly higher than the views of
people with SMA and their families where 70% of survey
participants were in favor (p < .001). Most participants
agreed that a newborn screening program would lead to
better support and health care for the child with SMA and
their family, it would help research into treatments by
enabling more children to be enrolled into clinical trials
early on and that it would enable parents to make informed
decisions about future pregnancies (Table 2). It is impor-
tant to note that 82% of the general population surveyed
agreed that despite the inability to diagnose an SMA type,
it is still important to have a diagnosis at birth (Table 2).
Of the questions asked regarding newborn screening,
there were significant differences in the answers given by the
general population and SMA families in nine of the 12 ques-
tions (Table 2). Arguably the most noticeable difference is
that a significantly larger percentage of the general popula-
tion surveyed agreed that identifying SMA at birth would
make the diagnosis easier for the parents to accept. However,
both groups agreed that identifying SMA at birth (and not in
pregnancy) removes the parents’ ability to make informed
decisions about bringing SMA children into the world, that it
would not interfere with the early bonding process between
parent and child and that it is not unethical to screen newborn
babies for conditions which lack treatments (Table 2). The
overall level of support for newborn genetic screening by the
general population is similar to the overall support for other
methods of SMA screening, namely preconception screening
(86%) and prenatal screening (84%).
3.3 | Why do the general population support
newborn screening for SMA?
Univariate logistic regression shows that participants who
were in support of a newborn genetic screening program
TABLE 1 Participant demographics
Characteristic
General population
(n = 232)
Gender – no. (%)
Male 73 (31)
Female 159 (69)
Age (%)
18–25 years 93 (40)
26–34 years 29 (12.5)
35–45 years 24 (10)
46–55 years 37 (16)
56–65 years 29 (12.5)
>66 years 20 (9)
Religious faith (%)
Yes 74 (32)
No 146 (63)
Prefer not to say 12 (5)
Children (do you have) (%)
Yes 111 (48)
No 120 (51.5)
Prefer not to say 1 (0.5)
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for SMA believe that it will improve health care, extend
the life expectancy of the child, improve research into treat-
ments, spare difficulties associated with finding a diagnosis
later on, and enable parents to make informed decisions
about future pregnancies (Table 3). In addition, they agree
that having a diagnosis at birth is important even if the par-
ticular type of SMA cannot be determined (Table 3). With
regard to negative drivers, participants who supported a
newborn screening program did not agree that identifying
SMA at birth would prevent enjoyment of life while the
TABLE 2 A comparison of SMA families and the general population (views on newborn screening)
Question
GenPop
(n = 232)
UK SMA population
(AwS and Families; n = 337) p-value
Q1. Identifying SMA at birth would lead to better support for children and families (%)
Agree 215 (93) 282 (84) .001
Other 17 (7) 55 (16)
Q2. Identifying SMA at birth would extend life expectancy of SMA children (%)
Agree 118 (51) 127 (38) .001
Other 114 (49) 210 (62)
Q3. Identifying SMA at birth and not during pregnancy removes parents ability to make informed decisions about bringing SMA children into
the world (%)
Agree 145 (63) 192 (57) .18
Other 87 (37) 145 (43)
Q4. Identifying SMA before symptoms emerge will prevent families and children enjoying life while they are symptom-free (%)
Agree 60 (26) 149 (44) <.0001
Other 172 (74) 188 (56)
Q5. Identifying SMA at birth will help research by enabling more children to be enrolled into clinical trials early on (%)
Agree 209 (90) 251 (74) <.0001
Other 23 (10) 86 (26)
Q6. Identification of SMA at birth would interfere with the early bonding process (%)
Agree 30 (13) 50 (15) .52
Other 202 (87) 287 (85)
Q7. Identification of SMA at birth would make the diagnosis easier for parents to accept (%)
Agree 118 (51) 100 (30) <.0001
Other 114 (49) 237 (70)
Q8. Identifying SMA at birth would spare the difficulties associated with finding a diagnosis for a child later on (%)
Agree 185 (80) 222 (66) .0003
Other 47 (20) 115 (34)
Q9. Identifying SMA at birth is important, even if the Type cannot be determined (%)
Agree 191 (82) 225 (67) <.0001
Other 41 (18) 112 (33)
Q10. Identifying SMA at birth is important because it will enable parents to make informed decisions about future pregnancies (%)
Agree 217 (94) 272 (81) <.0001
Other 15 (6) 65 (19)
Q11. It is unethical to screen newborns for conditions that have no effective treatment (%)
Agree 15 (6) 27 (8) .48
Other 217 (94) 310 (92)
Q12. I would support a Newborn screening program for SMA (%)
Agree 196 (84) 236 (70) <.0001
Other 36 (16) 101 (30)
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child is still symptom-free and that it would interfere with
the early bonding process between parent and child. In
addition, they did not agree that screening for conditions
which have no effective treatments is unethical (Table 3).
Multivariate logistic regression shows that those who
lent support to newborn genetic screening did so because
they believed it would lead to better support and healthcare
and it would also enable parents to make informed deci-
sions about future pregnancies. In addition, these partici-
pants believed that diagnosis was important even if the
type of SMA could not be determined and they disagreed
that it would interfere with the bonding process between
the parents and the SMA child (Table 4). Inclusion of age,
gender, qualification, and religious beliefs in the multivari-
ate model did not alter the factors identified as indepen-
dently associated with support, demonstrating there is no
bias within the demographics of the respondents.
4 | DISCUSSION
This research was conducted in order to gather the general
population’s views on a newborn screening program for
SMA in order to build on previous research that assessed
their views on carrier screening (Boardman, 2017), and
their contrast with the views of SMA families (Boardman
et al., 2017a,b,c). Together, this research was carried out
with the aim of assessing whether an SMA screening
TABLE 3 Univariate logistic regression showing positive and
negative drivers of newborn screening support in general population
Question Odds ratio (95% CI) p-value
Univariate logistic regression
Q1. Identifying SMA at birth would lead to better support for
children and families
Other Reference <.0001
Agree 7.83 (2.79–22.04)
Q2. Identifying SMA at birth would extend life expectancy of SMA
children
Other Reference .004
Agree 3.19 (1.46–6.97)
Q3. Identifying SMA at birth and not during pregnancy removes
parents ability to make informed decisions about bringing SMA
children into the world
Other Reference .09
Agree 184 (0.90–3.77)
Q4. Identifying SMA before symptoms emerge will prevent families
and children enjoying life while they are symptom-free
Other Reference .001
Agree 0.27 (0.13–0.57)
Q5. Identifying SMA at birth will help research by enabling more
children to be enrolled into clinical trials early on
Other Reference .04
Agree 2.72 (1.03–7.17)
Q6. Identification of SMA at birth would interfere with the early
bonding process
Other Reference .001
Agree 0.24 (0.10–0.57)
Q7. Identification of SMA at birth would make the diagnosis easier
for parents to accept
Other Reference .4
Agree 1.36 (0.66–2.77)
Q8. Identifying SMA at birth would spare the difficulties associated
with finding a diagnosis for a child later on
Other Reference .01
Agree 2.69 (1.24–5.84)
Q9. Identifying SMA at birth is important, even if the Type cannot
be determined
Other Reference <.0001
Agree 5.47 (2.51–11.94)
Q10. Identifying SMA at birth is important because it will enable
parents to make informed decisions about future pregnancies
Other Reference .0002
Agree 7.71 (2.60–22.93)
Q11. It is unethical to screen newborns for conditions that have no
effective treatment
Other Reference .0002
Agree 0.13 (0.04–0.39)
TABLE 4 Multivariate logistic regression showing most
significant positive and negative drivers of newborn screening
support in the general population
Multivariate logistic regression
Question Odds ratio (95% CI) p-value
Q1. Identifying SMA at birth would lead to better
support for children and families
Other Reference <.0001
Agree 6.07 (1.79–20.56)
Q6. Identification of SMA at birth would interfere with
the early bonding process
Other Reference .004
Agree 0.24 (0.09–0.63)
Q9. Identifying SMA at birth is important, even if the
Type cannot be determined
Other Reference .01
Agree 3.03 (1.23–7.46)
Q10. Identifying SMA at birth is important because it
will enable parents to make informed decisions about
future pregnancies
Other Reference .007
Agree 5.86 (1.61–21.32)
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program would be acceptable to the general population, a
key criterion when assessing the viability and feasibility
of any new screening program in the UK (UK NSC,
2015).
Overall, the survey results demonstrate that 84% of par-
ticipants from the general public were in favor of a new-
born genetic screening program for SMA, in contrast to
70% support among SMA families (Table 3). The key rea-
sons for screening support among the general population
were a belief that it would lead to better support and
healthcare and also that it would enable parents to make
informed decisions about future pregnancies. In addition,
the general public supported the notion that an early SMA
diagnosis is important, irrespective of the ability to diag-
nose the specific type of SMA. This finding is significant
as this limitation of the screening tests was considered a
serious impediment to the introduction of SMA screening
in the UK during the last policy review (Cartwright, 2012).
It is noteworthy, therefore, that this issue was not consid-
ered a fatal flaw within the screening program by either the
general population, or SMA-affected families (Boardman
et al., 2017a,b,c). For both groups, the importance of dis-
covering SMA as early as possible outweighed the value of
an accurate prognosis. In addition, the licensing of the first
therapeutic for SMA in December 2016, Nusinersen,
together with evidence that its efficacy is improved when
administered to presymptomatic children (Bertini et al.,
2017), is likely to further reinforce this viewpoint that ear-
lier identification of the condition is critical.
The two key areas where members of the general popu-
lation differed from SMA-affected families in terms of
screening support related to their acceptance of the diagno-
sis and the perceptions of the treatability of the condition
(Boardman et al., 2017b). Within the general population
sample, for example, there was a near 50/50 split between
those who agreed that identifying SMA at birth would
extend the life expectancy of the child (51% agree, 49%
other), and those who did not. This number is significantly
higher than among SMA families, for whom only 38%
agreed that life expectancy could be extended through early
diagnosis (Boardman et al., 2017b). This difference may
not only highlight the disparity in condition-specific knowl-
edge and experience between the general population and
affected families, but also points to the considerable cul-
tural belief among the general population in the ability of
medical interventions to alleviate, or even cure, chronic
conditions like SMA. SMA families, however, many of
whom had experienced the death of their child from SMA,
or who experienced it as a chronic, untreatable condition
were understandably more skeptical about the notion of
cure (Boardman et al., 2017a) and as such were less likely
to endorse this optimistic view that earlier identification
and treatment necessarily leads to better outcomes for
SMA children.
Another key area of divergence between the two popu-
lations related to the degree to which newborn screening
was deemed to facilitate diagnosis acceptance. Members of
the general population were considerably more likely to
agree that an early diagnosis would make the condition
easier for parents to accept than SMA families did (Board-
man et al., 2017b). There is conflicting data within the lit-
erature on the impact of a diagnosis when it is received via
a newborn screening program as opposed to after the onset
of clinical symptoms. Some studies suggest that an earlier
diagnosis, through screening, hastens the onset (and conse-
quently the resolution) of parental grief, enabling them to
more quickly come to terms with the condition and what it
means for their family and future (Young & Tattersall,
2007). Other studies, however, have suggested that a diag-
nosis before a child is symptomatic can have a substantial
negative impact on parental reactions. Grob (2008), for
example, has argued that an unanticipated and unsolicited
diagnosis may cause the early months of a child’s life to
become dominated by shock, anxiety and grief, which in
turn interferes with the bonding process between parent
and child (Grob, 2008). This reaction may indeed be exac-
erbated when the expected severity and life expectancy of
the child remain uncertain, and the child may appear to be
well and thriving at the point they are diagnosed with a
serious- and potentially fatal-genetic disorder. Indeed, in
contrast to the general population, data from SMA families
suggests that an SMA diagnosis is a difficult and painful
experience for parents irrespective of when it is delivered
(Boardman, 2010; Lawton, Hickerton, Archibald, McCla-
ren, & Metcalfe, 2015), suggesting that earlier identifica-
tion through newborn screening is unlikely to significantly
reduce this impact.
Despite these two areas of contrast, however, the key
reasons for supporting a newborn screening program
appeared to be largely consistent between the general popu-
lation and SMA families. This highlights that despite con-
trasting vantage points and experiences of the condition,
both groups regarded early identification of SMA as the
most significant benefit of newborn screening, even if an
effective treatment was not available. This conviction
underscores the importance of considering the experiences
and viewpoints of the whole family when assessing the
harms and benefits of newborn screening. For while, early
identification in the absence of treatments may not have
immediate and/or direct benefit to the child, the participants
in this survey highlighted that there may, nevertheless, be
considerable benefits to the family unit, including enhanced
parental adjustment, acceptance of the condition, and future
pregnancy planning.
BOARDMAN ET AL. | 7
When viewed in comparison to other forms of screen-
ing, the general population demonstrated the same level of
support for a prenatal screening program as for a newborn
one (84%). However, preconception screening was overall
the most favored method of screening (86%) (Boardman
et al., 2017a,b,c). This is in line with the views of SMA
families who also favored preconception screening (77%),
over prenatal (76%) and newborn screening (70%) (Board-
man et al., 2017b,c). This suggests that although both
groups agree that there are significant benefits to newborn
screening, that the advantages of preconception screening
(the possibility of avoiding the creation or carrying to term
of SMA-affected embryos/fetuses through early carrier
identification) were viewed as more effective in tackling
SMA than those associated with newborn screening, which
instead focuses on treating infants who are already affected
by SMA (Boardman, 2017; Boardman et al., 2017c).
Overall, this study highlights that the majority of the
general population are in favor of newborn screening for
SMA irrespective of the inability to diagnose the child with
a particular type of SMA and despite the limited treatment
options that are available. Newborn screening, unlike pre-
conception and prenatal screening, does not potentially
involve termination of pregnancy and for this reason is the
least controversial screening method for SMA, particularly
in the context of uncertain prognostic information. In addi-
tion, this screening method is the most likely to accelerate
research into treatments by allowing early enrollment onto
clinical trials, which is particularly important for conditions
like SMA where symptom-onset can be very early in life
and the number of treatment options limited.
4.1 | Limitations
Due to the anonymity of the survey link distributed, there
was no way of preventing a respondent from completing the
survey more than once. In addition, a high number of respon-
dents were aged 18–25 years old (40%) and a significantly
higher percentage of women responded to the survey than
men (69% and 31% respectively). However, forward logistic
regression taking into account gender, age, qualifications,
and religion, showed no change in the main drivers behind
support. Therefore, there appears to be no bias among the
demographics of the respondents. Last, the final potential
limitation could be the survey responder’s limited knowledge
of SMA. Although information on SMA was provided at the
start of the survey in order to overcome this, some may argue
that this information was not sufficient enough for the
respondents to have a clear picture of the condition, or an
understanding of what living with the condition on a day-to-
day basis would be like. Similarly, it could be argued that the
general population have not experienced the everyday diffi-
culties associated with the condition and therefore have an
altered perception of SMA which may affect the answers
given. Nevertheless, responders were provided with back-
ground information before starting the survey and were free
to pause the survey while they did their own independent
research. They were then able to continue with the survey
when they were happy they had gathered sufficient back-
ground knowledge of SMA and were therefore able to make
informed decisions in order to answer the questions.
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